Mesoblast Financial Results and Corporate Update Webcast

Rhea-AI Summary

Mesoblast (Nasdaq:MESO, ASX:MSB) will host a webcast to review operational highlights and financial results for the full year ended June 30, 2026. The webcast begins at 6:30pm EDT on Wednesday, August 26 and 8:30am AEST on Thursday, August 27, 2026, accessible at https://webcast.openbriefing.com/msb-fyr-2026/, with an archived version on the company’s investor page.

Mesoblast develops allogeneic cellular medicines from its mesenchymal lineage cell therapy platform. Its product Ryoncil (remestemcel-L-rknd) is described as the first FDA-approved mesenchymal stromal cell therapy for pediatric SR-aGvHD, and the company advances additional indications and candidates including rexlemestrocel-L.

Market Context

At publication, SRPT was down -3.09%, while peers were mixed. That platform context placed Mesoblast...

Analysis

At publication, SRPT was down -3.09%, while peers were mixed. That platform context placed Mesoblast’s scheduling notice within a weaker biotechnology tape; the key watchpoint remained the financial results to be discussed.

Key Figures

Fiscal period: Full year ended June 30, 2026 Webcast start: 6.30pm EDT, August 26, 2026 Patient age: 2 months and older +2 more

5 metrics

Fiscal period Full year ended June 30, 2026 Financial results to be discussed

Webcast start 6.30pm EDT, August 26, 2026 Scheduled webcast

Patient age 2 months and older Ryoncil indication

Patent portfolio Over 1,000 granted patents or patent applications Mesoblast intellectual property portfolio

Commercial protection At least 2044 Protection in all major markets

Previous Earnings Reports

5 past events · Latest: Feb 20 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 20	Half-year webcast notice	Neutral	-0.2%	Scheduled webcast covering half-year operational highlights and financial results
Aug 27	Full-year webcast notice	Neutral	+0.8%	Scheduled webcast covering full-year financial results and operational highlights
Feb 25	Half-year webcast notice	Neutral	-2.1%	Scheduled webcast covering half-year operational highlights and financial results
Aug 28	Full-year financial results	Neutral	+1.6%	Reported fiscal-year results alongside regulatory and clinical development updates
Aug 27	Full-year webcast notice	Neutral	+0.2%	Scheduled webcast covering full-year operational highlights and financial results

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Earnings-tagged events produced mixed reactions, ranging from -2.06% to 0.75%, with an average move of 0.05.

Key Terms

allogeneic, mesenchymal stromal cell, cryopreserved, effector arms

4 terms

allogeneic medical

"Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

mesenchymal stromal cell medical

"the first FDA-approved mesenchymal stromal cell (MSC) therapy"

Mesenchymal stromal cells are a type of adult cell found in bone marrow, fat and other tissues that can act like a repair crew, supporting tissue healing, reducing inflammation and helping other cells grow. Investors care because these cells are the basis for many experimental therapies and diagnostics; clinical success, manufacturing scale-up, safety and regulatory approval determine commercial potential and can strongly affect a company’s valuation.

cryopreserved medical

"industrial-scale, cryopreserved, off-the-shelf, cellular medicines"

Cryopreserved means biological material—such as cells, tissues, blood, vaccines, or other biologics—has been cooled to very low temperatures to stop biological activity and preserve viability for long-term storage. For investors, cryopreservation matters because it affects product shelf life, regulatory handling, manufacturing and distribution logistics, and the timing of when a usable biological product can be retrieved, much like keeping perishable food in a deep freezer to pause spoilage.

effector arms medical

"counter and modulate multiple effector arms of the immune system"

Effector arms are the cells, molecules, and pathways in the immune system that actually carry out a response after an initial signal or activation—for example, killer T cells destroying infected cells or antibodies neutralizing pathogens. They matter to investors because therapies or diagnostics that engage, enhance, or suppress specific effector arms determine how well a treatment works and its likely safety profile, much like the tools a crew uses to execute a plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026.

The webcast will begin at 6.30pm EDT, Wednesday, August 26; 8.30am AEST, Thursday, August 27, 2026. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2026/

The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global	Media – Australia
Rubenstein	BlueDot Media
Caroline Nelson	Steve Dabkowski
T: +1 703 489 3037	T: +61 419 880 486
E: cnelson@rubenstein.com	E: steve@bluedot.net.au

FAQ

When is Mesoblast (MESO) holding its full-year 2026 financial results webcast?

Mesoblast is holding its full-year 2026 financial and operational results webcast on Wednesday, August 26 at 6:30pm EDT, which is Thursday, August 27, 2026 at 8:30am AEST. According to Mesoblast, this webcast covers the year ended June 30, 2026.

How can investors access the Mesoblast (MESO) FY 2026 results webcast and replay?

Investors can access the Mesoblast webcast at https://webcast.openbriefing.com/msb-fyr-2026/. According to Mesoblast, an archived replay will be available on the company’s Investor page at www.mesoblast.com, allowing shareholders to review the financial and operational discussion later.

What products and indications is Mesoblast (MESO) highlighting around its FY 2026 webcast?

Mesoblast is highlighting its allogeneic cellular medicines, including Ryoncil (remestemcel-L-rknd) and rexlemestrocel-L. According to Mesoblast, Ryoncil targets steroid-refractory acute graft versus host disease, while rexlemestrocel-L is being developed for heart failure and chronic low back pain indications.

What is Ryoncil (remestemcel-L-rknd) mentioned in the Mesoblast (MESO) webcast notice?

Ryoncil is Mesoblast’s mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease. According to Mesoblast, it is described as the first FDA-approved MSC therapy and is being developed for additional inflammatory diseases, including adult SR-aGvHD and biologic-resistant inflammatory bowel disease.

What intellectual property protection does Mesoblast (MESO) report for its cell therapies?

Mesoblast reports a global portfolio of over 1,000 granted patents or applications covering compositions, manufacturing, and indications. According to Mesoblast, these patents and applications provide commercial protection extending through at least 2044 in all major markets, underpinning its allogeneic cell therapy platforms.

Where does Mesoblast (MESO) manufacture its allogeneic cell therapies?

Mesoblast uses proprietary processes to manufacture industrial-scale, cryopreserved, off-the-shelf cell therapies. According to Mesoblast, the company operates across locations in Australia, the United States, and Singapore, aiming to make products with defined pharmaceutical release criteria available to patients worldwide.